Coursera Flash Sale
40% Off Coursera Plus for 3 Months!
Grab it
Learn about low-dose naltrexone (LDN) as a repurposed cancer treatment through this 20-minute educational video featuring Professor of Oncology Angus Dalgleish. Discover how naltrexone, originally designed to block opioid receptors for addiction treatment, shows promising potential in cancer therapy when administered at very low doses. Explore the three primary mechanisms through which LDN may influence cancer progression: antagonism of toll-like receptors 7-9 leading to IL-6 suppression, modulation of immune function in patients, and direct inhibition of cancer cell signaling pathways including pro-apoptotic pathway priming. Examine the growing body of anecdotal evidence supporting cancer resolution following LDN use, and understand why this has led to increased interest in oncological applications. Review clinical evidence from systematic research and consider the potential for LDN use in combination with conventional chemotherapy treatments. Access additional resources including research papers on naltrexone's relevance to cancer therapy and information from the LDN Research Trust to deepen your understanding of this neglected but potentially valuable cancer treatment approach.
